Every 8-K that Ardelyx, Inc. (ARDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ARDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARDX filings page.
Ardelyx, Inc. reported a leadership change with the resignation of its Chief Commercial Officer, Eric Foster. Foster informed the company of his decision on August 11, 2026, and his resignation is effective August 28, 2026. The company states that he is leaving to pursue a new opportunity with a pre-commercial company and that his resignation is not due to any disagreement with Ardelyx. Ardelyx remains incorporated in Delaware and its common stock, par value $0.0001 per share, continues to trade under the symbol ARDX on The Nasdaq Global Market.
Ardelyx reported record second-quarter 2026 results, with total product revenue of $118.1 million for the quarter ended June 30, 2026, a 31% year-over-year increase driven by strong demand for IBSRELA and XPHOZAH. IBSRELA generated $86.2 million, up 33%, and XPHOZAH $31.9 million, up 27%.
The company recorded a net loss of $16.7 million, or $(0.07) per share, compared with a net loss of $19.1 million, or $(0.08) per share, a year earlier. As of June 30, 2026, cash, cash equivalents and short-term investments totaled $281.8 million, including a $50 million debt drawdown on June 29, 2026.
Full-year 2026 IBSRELA revenue guidance was revised to $350–$370 million from $410–$430 million, while XPHOZAH guidance of $110–$120 million was reiterated and operating expense guidance was lowered to below $500 million. Ardelyx maintains its $1 billion long-term IBSRELA revenue goal, is advancing the Phase 3 ACCEL trial in chronic idiopathic constipation with top-line data expected in the second half of 2027, and continues development of next-generation NHE3 inhibitor RDX10531.
Ardelyx, Inc. drew a new $50.0 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders to fund general corporate purposes and support strategic initiatives. The loan matures on July 1, 2030 and carries interest at 4.55% plus the greater of the 1‑month SOFR reference rate or 3.5%. Ardelyx is permitted to make interest‑only payments on this loan until maturity. The agreement includes customary events of default that could make the debt immediately due and allow the lenders to enforce on collateral, including the company’s cash, with default interest of an additional 4.0% per annum during any default period.
Ardelyx, Inc. reported results of its 2026 Annual Meeting, where stockholders approved all five proposals, including changes to its long-term incentive plan and auditor ratification.
Stockholders elected three Class III directors to serve until the 2029 Annual Meeting. They approved, on a non-binding basis, the company’s Say-On-Pay proposal and selected an annual Say-On-Pay vote, with 141,539,889 votes cast for a one-year frequency.
Investors ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 186,182,340 votes in favor. They also approved the Second Amendment to the Amended and Restated 2014 Equity Incentive Award Plan.
Ardelyx reported strong first quarter 2026 growth while remaining loss-making. Total product revenue reached $93.4 million for the quarter ended March 31, 2026, up 38% from $67.8 million a year earlier, driven mainly by IBSRELA sales of $70.1 million, which grew 58% year-over-year.
XPHOZAH contributed $23.3 million in revenue, and total revenue including other items was $94.5 million. Operating expenses rose as Ardelyx invested in commercialization and R&D, leading to a net loss of $37.6 million, or $(0.15) per share, slightly improved from a $41.1 million loss a year earlier. The company ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and reiterated 2026 revenue guidance of $410–$430 million for IBSRELA and $110–$120 million for XPHOZAH, while advancing its pipeline, including the Phase 3 ACCEL trial in chronic idiopathic constipation and preclinical candidate RDX10531.
Ardelyx reported full-year 2025 revenue of $407.3 million, up from $333.6 million in 2024, driven by strong growth in its IBSRELA and XPHOZAH franchises. IBSRELA revenue rose to $274.2 million, a 73% increase from $158.3 million, while XPHOZAH revenue was $103.6 million, down from $160.9 million.
The company posted a 2025 net loss of $61.6 million, or $(0.26) per share, compared with a net loss of $39.1 million in 2024, as R&D expenses grew to $71.5 million and SG&A reached $337.2 million. Cash, cash equivalents and short-term investments were $264.7 million as of December 31, 2025.
For 2026, Ardelyx guides to product revenue of $520–$550 million, including IBSRELA revenue of $410–$430 million and XPHOZAH revenue of $110–$120 million, with operating expenses up to $520 million. The company is advancing a Phase 3 ACCEL trial for tenapanor in chronic idiopathic constipation and preparing an IND submission in the second half of 2026 for next‑generation NHE3 inhibitor RDX10531.
Ardelyx, Inc. reported preliminary, unaudited product sales for 2025. U.S. net product sales revenue of IBSRELA® (tenapanor) was approximately $87 million in the fourth quarter and approximately $274 million for the full year ended December 31, 2025. U.S. net product sales revenue of XPHOZAH® (tenapanor) was approximately $28 million in the fourth quarter and approximately $104 million for the full year.
The company also indicated it had approximately $265 million in cash, cash equivalents, and short-term investments as of December 31, 2025, on an unaudited basis. All figures are preliminary, may be adjusted during the audit process, and have not been audited or reviewed by Ernst & Young LLP.
Ardelyx, Inc. reported senior leadership changes effective December 31, 2025. Elizabeth Grammer resigned as Chief Legal and Administrative Officer, but will continue as General Counsel until a successor is named and then serve as a Senior Advisor for 24 months under a Transition and Separation Agreement. During an initial 12‑month employment period, she will keep her current base salary, remain eligible for an annual target bonus equal to 45% of base salary for 2025, and continue to receive senior non‑executive benefits, followed by a one‑month salary payment if she delivers a general release.
In the second 12 months, her equity will continue to vest, she may receive advisory payments for the first nine months, and Ardelyx will pay COBRA health premiums for her and dependents during the advisory term or until she gains other coverage. Separately, Chief Medical Officer Edward Conner, M.D. will resign for personal reasons, and Chief Patient Officer and former CMO Dr. Laura Williams will act as interim Chief Medical Officer, overseeing clinical development until a permanent replacement is hired.
Ardelyx, Inc. filed a current report stating that on October 30, 2025 it announced its financial results for the quarter ended September 30, 2025. The company furnished the full text of the related earnings press release as Exhibit 99.1, rather than treating it as filed, which affects how it may be used in future securities law filings. The report also notes the inclusion of an Inline XBRL cover page data file as Exhibit 104.
Ardelyx appointed Sue Hohenleitner as chief financial officer and principal financial officer, effective November 4, 2025. She brings senior finance experience from Johnson & Johnson, including serving as CFO of J&J Innovative Medicine North America.
Her compensation includes an annual base salary of $550,000 and a target bonus equal to 45% of base salary, pro‑rated for fiscal 2025. Upon her employment commencement on October 13, 2025, she received a sign‑on bonus of $180,000 and a housing consideration payment of $150,000. Equity awards granted on October 13, 2025 comprise an option to purchase 578,104 shares at an exercise price of $5.01 per share, vesting over four years (25% after one year, then monthly over 36 months), and 146,896 restricted stock units vesting 25% on the first quarterly vest date after the one‑year anniversary, then quarterly over three years. The company plans to enter into its standard indemnification and change‑in‑control severance agreements with her.
Ardelyx, Inc. (ARDX) has amended its February 2022 Loan & Security Agreement for the fifth time, securing an immediate $50 million senior secured term loan ("Term E") and gaining access to an additional $100 million of committed capital in two optional $50 million tranches ("Term F" and "Term G").
Key economics include: (1) Term E pricing at 4.00% plus 0.022% plus 1-month SOFR, with a SOFR floor of 4.70%; (2) optional Term F/G pricing at SOFR + 4.95%, floored at 3.50%; (3) interest-only payments until maturity—July 1, 2028 for Term E and July 1, 2030 for Term F/G. The company paid a $250k draw fee for Term E and a $1.0 million facility fee for the incremental loans.
The facility remains collateralized and carries back-end fees of 4.95% (Term E) and 3.45% (Term F/G) of principal, payable upon maturity, acceleration, or prepayment. No changes were disclosed to covenants or security packages.
Investment view: The amendment immediately bolsters liquidity and provides flexible growth or runway capital through 2026, but materially increases secured debt capacity and locks in high floating-rate interest costs. Investors should weigh the near-term cash benefit against potential future leverage and interest-expense drag.
Ardelyx held its 2025 Annual Meeting of Stockholders on June 18, 2025, where shareholders voted on four key proposals. 187,162,927 shares out of 239,255,212 outstanding shares were represented at the meeting.
Key outcomes include:
- Board Elections: Class II directors David Mott and Michael Raab were elected to serve until 2028, with Raab receiving stronger shareholder support (101.2M vs 93M votes)
- Say-on-Pay: Approved with strong support (131.3M votes in favor)
- Auditor Ratification: Ernst & Young LLP confirmed as independent auditor with overwhelming approval (182.5M votes in favor)
- Equity Plan Amendment: The amendment to the Amended and Restated 2014 Equity Incentive Award Plan passed with moderate support (85M votes for vs 57.4M against)
The meeting demonstrated generally positive shareholder sentiment, though the Equity Plan Amendment faced notable opposition with approximately 40% of voting shares against the proposal.